Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: In vivo and in vitro studies

Journal of Physiology and Pharmacology

Volumn 58, Issue 4, 2007, Pages 829-843

  Juszczak, Marlena ^a,b   Boczek Leszczyk, E ^a   Stempniak, B ^b  

^a Department of Pathophysiology and Experimental Neuroendocrinology ^*  (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Melatonin; Neurokinin A; NK 1 NK 2 receptors; Substance P; Vasopressin

Indexed keywords

MELATONIN; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR AGONIST; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ A [4-10][BETA ALANINE 8]; NEUROKININ A [4-10][TYROSINE 5 DEXTRO TRYPTOPHAN 6,8,9 LYSINE AMIDE 10]; SUBSTANCE P; SUBSTANCE P [6-11][TYROSINE 6 DEXTRO PHENYLALANINE 7 DEXTRO HISTIDINE]; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HORMONE RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROHYPOPHYSIS; NONHUMAN; RADIOIMMUNOASSAY; RAT;

ANALYSIS OF VARIANCE; ANIMALS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MELATONIN; NEUROKININ A; NEUROTRANSMITTER AGENTS; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SUBSTANCE P; VASOPRESSINS;

EID: 38149065346     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bittencourt JC, Benoit R, Sawchenko PE. Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: partial overlap with ascending catecholaminergic projections. J Chem Neuroanat 1991; 4: 63-78.
2. Mikkelsen JD, Schmidt P, Sheikh SP, Larsen PJ. Non-vasopressinergic, non-oxytocinergic neuropeptides in the rat hypothalamo-neurohypophyseal tract: experimental immunohistochemical studies. Prog Brain Res 1992; 91: 367-371.
3. Chowdrey HS, Lightman SL. Role of central amino acids and peptide-mediated pathways in neurohypophysial hormone release. Ann NY Acad Sci 1993; 689: 183-193.
4. Sladek CD, Kapoor JR. Neurotransmitter/neuropeptides interactions in the regulation of neurohypophysial hormone release. Exp Neurology 2001; 171: 200-209.
5. Maggio J. Tachykinins. Ann Rev Neurosci 1988; 11: 13-28.
6. Juszczak M. Neurokinin A and the neurohypophysial response to melatonin: in vitro studies. J Physiol Pharmacol 2002; 53: 823-834.
7. Juszczak M, Stempniak B. Melatonin inhibits the substance P-induced secretion of vasopressin and oxytocin from the rat hypothalamo-neurohypophysial system: in vitro studies. Brain Res Bull 2003; 59: 393-397.
8. Debeljuk L, Lasaga M. Tachykinins and the control of prolactin secretion. Peptides 2006; 27: 3007-3019.
9. Larsen PJ, Jessop DS, Chowdrey HS, Mikkelsen JD, Lightman SL. Osmotic regulation of substance P and neurokinin A peptide content and substance P binding sites in distinct hypothalamic nuclei of the rat. Peptides 1992; 13: 705-712.
10. Larsen PJ, Jessop DS, Lightman SL, Chowdrey HS. Preprotachykinin A gene expression in distinct hypothalamic and brain stem regions of the rat is affected by a chronic osmotic stimulus: a combined immunohistochemical and in situ hybridization histochemistry study. Brain Res Bull 1993; 30: 535-545.
11. Duval P, Lenoir V, Moussaoui S, Garret C, Kerdelhue B. Substance P and neurokinin A variations throughout the rat oestrous cycle; comparison with ovariectomized and male rats: I. Plasma, hypothalamus, anterior and posterior pituitary. J Neurosci Res 1996; 45: 598-609.
12. Ding YQ, Lu BZ, Guan ZL, Wang DS, Xu JQ, Li JH. Neurokinin B receptor (NK3)-containing neurons in the paraventricular and supraoptic nuclei of the rat hypothalamus synthesize vasopressin and express Fos following intravenous injection of hypertonic saline. Neuroscience 1999; 91: 1077-1085.
13. Haley GE, Flynn FW. Agonist and hypertonic saline-induced trafficking of the NK3-receptors on vasopressin neurons within the paraventricular nucleus of the hypothalamus. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1242-1250.
14. Hatae T, Kawano H, Karpitsky V, Krause JE, Masuko S. Arginine-vasopressin neurons in the rat hypothalamus produce neurokinin B and co-express the tachykinin NK-3 receptor and angiotensin II type 1 receptor. Arch Histol Cytol 2001; 64: 37-44.
15. Heike Y, Hisano S, Tsurvo Y, Katoh S, Daikoku S. Immunocytochemical evidence for synaptic regulation of paraventricular vasopressin-containing neurons by substance P. Brain Res 1986; 396: 341-346.
16. Guartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1988; 32: 1-49.
17. Hagan RM, Beresford IJM, Stables J, et al. Characterization, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Reg Pept 1993; 46: 9-19.
18. Torrens Y, Beaujouan J-C, Dietl M, Saffroy M, Petitet F, Glowinski J. Tachykinin receptors: binding and cellular activity assays. Methods Neurosci 1991; 5: 243-267.
19. Kapoor JR, Sladek CD. Substance P and NPY differentially potentiate ATP and adrenergic stimulated vasopressin and oxytocin release. Am J Physiol 2001; 280: R69-78.
20. Juszczak M. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists. Neuroendocrinology Letters 2005; 26: 367-372.
21. Chiodera P, Coiro V. Effects of intravenous infusion of substance P on arginine vasopressin and oxytocin secretion in normal men. Brain Research 1992; 569: 173-176.
22. Chowdrey HS, Jessop DS, Lightman SL. Substance P stimulates arginine vasopressin and inhibits adrenocorticotropin release in vivo in the rat. Neuroendocrinology 1990; 52: 90-93.
23. Massi M, Saija A, Polidori C, et al. The hypothalamic paraventricular nucleus is a site of action for the central effect of tachykinin on plasma vasopressin. Brain Res Bull 1991; 26: 149-154.
24. Harlan RE, Garcia MM, Krause JE. Cellular localization of substance P- and neurokinin A-encoding preprotachykinin mRNA in the female rat brain. J Comp Neurol 1989; 287: 179-212.
25. Nevin K, Zhuo H, Helke CJ. Neurokinin A coexists with substance P and serotonin in ventral medullary spinally projecting neurons of the rat. Peptides 1994; 15: 1003-1011.
26. Juszczak M, Furykiewicz-Nykiś K, Stempniak B. Role of tachykinin receptors and melatonin in oxytocin secretion from isolated rat hypothalamo-neurohypophysial system. J Physiol Pharmacol 2004; 55: 739-749.
27. Juszczak M. The hypothalamo-neurohypophysial response to melatonin. Neuroendocrinol Lett 2001; 22: 169-174.
28. Wu YH, Zhou JN, Balesar R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotrophin-releasing hormone. J Comp Neurol 2006; 499: 897-910.
29. 3-norepinephrine into the lateral ventricle of the brain. Life Sci 1967; 6: 281-291.
30. Ciosek J, Guzek JW, Orłowska-Majdak M. Thyrotropin-releasing hormone (TRH) modulates vasopressin and oxytocin release from the hypothalamo-neurohypophysial system in dehydrated rats. J Physiol Pharmacol 1993; 44: 293-302.
31. Juszczak M, Bojanowska E, Da̧browski R. Melatonin and the synthesis of vasopressin in pinealectomized male rats. P Soc Exp Biol Med 2000; 225: 207-210.
32. Yasin SA, Grossman A, Forsling ML. Diurnal variation in the effect of melatonin on neurohypophysial hormone release from the rat hypothalamus. Brain Res Bull 1996; 39: 1-5.
33. Lipińska S, Foryś S, Lipińska J. The post-haemorrhagic vasopressin release into the blood. J Physiol Pharmacol 2004; 55: 73-83.
34. Lipińska S, Żebrowska-Badalla A, Lipińska J. Oxytocin release after bleeding in rat: the role of sympathetic and renin-angiotensin system. J Physiol Pharmacol 2006; 57: 627-636.
35. Cisowska-Maciejewska A, Ciosek J. Galanin influences vasopressin and oxytocin release from the hypothalamo-neurohypophysial system of salt-loaded rats. J Physiol Pharmacol 2005; 56: 673-688.
36. Juszczak M, Bojanowska E, Guzek JW, Stempniak B, Dabrowski R. The effect of melatonin on vasopressin release under stress conditions in pinealectomized male rats. Adv Exp Med Biol 1999; 460: 311-315.
37. Clarke G, Kirby PJC, Thomson AM. Effect on vasopressinergic and oxytocinergic neurones of intraventricular substance P. J Physiol (London) 1980; 307: 59P.
38. Baruch P, Artaud F, Godeheu G, Barbeito L, Glowinski J, Cheramy A. Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrities and nerve terminals of the nigrostriatal dopaminergic neurons. Neuroscience 1988; 25: 889-898.
39. Vitte PA, Harthe C, Lestage P, Claustrat B, Bobillier P. Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: a biochemical and autoradiographic study. J Pineal Res 1988; 5: 437-453.
40. Bojanowska E, Forsling ML. The effect of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Brain Res Bull 1997; 22: 457-461.
41. Forsling ML, Achaaban AR, Zhou Y. The effect of intracerebroventricular melatonin on vasopressin release in the conscious rat. J Endocrinol 1992; 135: Suppl. P47.
42. Windle RJ, Forsling ML, Guzek JW. Daily rhythms in the hormone content of the neurohypophysial system and release of oxytocin and vasopressin in the male rat: effect of constant light. J Endocrinol 1992; 133: 283-290.
43. Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia 1993; 49: 654-664.
44. Yasin SA, Forsling ML. Mechanisms of melatonin inhibition of neurohypophysial hormone release from the rat hypothalamus in vitro. Brain Res Bull 1998; 45: 53-59.
45. Reiter RJ, Oh C-S, Fujimori O. Melatonin: its intracellular and genomic actions. Trends Endocrinol Metab 1996; 7: 22-27.
46. Wiesenberg I, Missbach M, Kahlen J-P, Schrader M, Carlberg C. Transcriptional activation of the nuclear receptor RZRa by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res 1995; 23: 327-333.
47. Dardente H, Klosen P, Pévet P, Masson-Pévet M. MT1 melatonin receptor mRNA expressing cells in pars tuberalis of the European hamster: effect of photoperiod. J Neuroendocrinol 2003; 15: 778-786.
48. 1a) receptor and arginine vasopressin mRNAs in the Siberian hamster suprachiasmatic nucleus. J Neuroendocrinol 2000; 12: 627-634.
49. Isobe Y, Torii T, Nishino H. Melatonin inhibits Arg-vasopressin release via MT2 receptor in the suprachiasmatic nucleus-slice culture of rats. Brain Res 2001; 889: 214-219.
50. Mikkelsen JD, Larsen PJ. Substance P in the suprachiasmatic nucleus of the rat: an immunohistochemical and in situ hybridization study. Histochemistry 1993; 100: 3-16.
51. Hermes MLHJ, Coderre EM, Buijs RM, Renaud LP. GABA and glutamate mediate rapid neurotransmission from suprachiasmatic nucleus to hypothalamic paraventricular nucleus in rat. J Physiol 1996; 496: 749-757.
52. Cui LN, Saeb-Parsy K, Dyball REJ. Neurons in the supraoptic nucleus of the rat are regulated by a projection from the suprachiasmatic nucleus. J Physiol 1997; 502: 149-159.
53. Alexiuk NAM, Uddin M, Vriend JP. Melatonin increases the in situ activity of tyrosine hydroxylase in the mediobasal hypothalamus of male Syrian hamsters. Life Sci 1996; 59: 687-694.
54. Miguez JM, Aldegunde M. Changes in the hypothalamic serotonergic function may mediate the endocrine effects of melatonin. J Physiol Biochem 1996; 52: 239-246.
55. Pawlikowski M, Juszczak M, Karasek E, Muszyńska B, Karasek M. Melatonin inhibits prostaglandyn E release from the medial basal hypothalamus of pinealectomized rats. J Pineal Res 1984; 1: 317-321.
56. Massi M, Polidori C, Perfumi M, Gentili L, De Caro G. Tachykinin receptor subtypes involved in the central effects of tachykinins on water and salt intake. Brain Res Bull 1991; 26:155-160.